Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 280 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the economic evaluation of health care programmes (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and Decision modelling for health economic evaluation (OUP, 2006 with Briggs and Claxton). He was also a member of the Second Panel on Cost-Effectiveness in Health and Medicine.
Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee (2004-8), the NICE Public Health Interventions Advisory Committee (2006-9) and the NICE Diagnostics Advisory Committee (2010-20). He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme (2007-10), the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel (2008-11) and the MRC-NIHR Methodology Research Advisory Group (2016-20). He was a member of the NIHR Policy Research Programme’s Commissioning Panel (2011-14). Mark is a NIHR Senior Investigator (Emeritus) and is a former President of the International Society of Pharmacoeconomics and Outcomes Research.
Recent national and international advisory roles include the Singapore Agency for Care Effectiveness International Advisory Panel (2017-18); UK Health Select Committee Availability of Orkambi on the NHS inquiry (2018-19); Portuguese National Authority of Medicines and Health Products (2018-20).